

# Migra Eze

Synergistic Nutritional Support for Cerebral Circulation\*

Migra Eze is a comprehensive vitamin and herbal formula designed to support healthy brain function. Globally, more than 15% of the population are affected by cranial vascular issues, which are believed to start in adolescence and worsen with aging.<sup>1</sup> The causes of such issues appear to be both genetic and environmental (such as dietary triggers and external stressors).

# How Migra Eze Works

We formulated Migra Eze with efficacious, clinically-researched ingredients shown to support healthy stress response and vascular health in the brain.<sup>•</sup> The unique ingredient profile of Migra Eze includes key micronutrients for supporting brain health, including vitamin B2 (riboflavin) and magnesium.<sup>2</sup>

Migra Eze also contains select herbal ingredients, including ginger root powder, feverfew, butterbur root and ginkgo biloba, that work synergistically to promote cranial vascular health and support healthy inflammatory response.<sup>43,4,5,6</sup>

# **Migra Eze Supplementation**

Clinical research suggests that the ingredients in Migra Eze can help support cranial vascular health.<sup>42,3,4,5,6,7</sup> It appears these ingredients work to support healthy inflammation and neurotransmission, both of which have been associated with proper cranial vascular health.<sup>41</sup>

Clinical research suggests the primary benefits of Migra Eze supplementation may include:

- Supports and promotes cranial vascular health\*
- Supports healthy vascular function<sup>+</sup>
- Promotes healthy neurotransmitter balance in the brain<sup>+</sup>



## Form: 120 Capsules Serving Size: 2 Capsules

Ingredients	Amount	% <b>DV</b>
Riboflavin (as riboflavin-5-phosphate)	190 mg	11,176%
Magnesium (as magnesium citrate)	100 mg	24%
Ginger Extract (root; <i>Zingiber officinale</i> ; standardized to 5% gingerols and shogaols	250 mg s)	**
Feverfew Extract (aerial parts; <i>Tanacetum</i> parthenium; standardized to 0.2% partheni	50 mg olide)	**
Butterbur 6:1 Extract (root; <i>Petasites hybridus</i> )	50 mg	**
Ginkgo Extract (leaf; Ginkgo biloba)	40 mg	**

## Other Ingredients:

Hypromellose, microcrystalline cellulose, vegetable magnesium stearate, silica.

## **Directions:**

Take two capsules twice daily, as a dietary supplement, or as directed by your healthcare practitioner.

**Caution:** If you are pregnant, nursing, or taking medication, consult your healthcare practitioner before use. Keep out of reach of children.



These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.



#### **References:**

- Vos, T; Flaxman, AD; Naghavi, M; Lozano, R; Michaud, C; Ezzati, M; Shibuya, K; Salomon, JA; et al. (2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010". *Lancet*. 380 (9859): 2163–96.
- 2. Maizels, M., Blumenfeld, A., & Burchette, R. (2004). A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. *Headache: The Journal of Head and Face Pain, 44*(9), 885-890.
- 3. Malhotra, S., & Singh, A. P. (2003). Medicinal properties of ginger (Zingiber officinale Rosc.). Natural product radiance, 2(6), 296-301.
- Johnson, E. S., Kadam, N. P., Hylands, D. M., & Hylands, P. J. (1985). Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed), 291(6495), 569-573.
- 5. Taylor, F. R. (2009). Lifestyle changes, dietary restrictions, and nutraceuticals in migraine prevention. *Techniques in regional anesthesia and pain management*, *13*(1), 28-37.
- 6. D'Andrea, G., Bussone, G., Allais, G., Aguggia, M., D'Onofrio, F., Maggio, M., ... & Benedetto, C. (2009). Efficacy of Ginkgolide B in the prophylaxis of migraine with aura. *Neurological sciences*, 30(1), 121-124.
- 7. Sun-Edelstein C, Mauskop A (June 2009). "Foods and supplements in the management of migraine headaches". The Clinical Journal of Pain. 25 (5): 446–52.